| scholarly article | Q13442814 |
| P50 | author | Sundeep Khosla | Q42164143 |
| P2093 | author name string | Jennifer J Westendorf | |
| Merry Jo Oursler | |||
| Ming Ruan | |||
| Larry Pederson | |||
| Patrick Quint | |||
| Kuniaki Ota | |||
| P2860 | cites work | TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation | Q37307155 |
| Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer | Q37364633 | ||
| Molecular mechanisms in coupling of bone formation to resorption. | Q37385000 | ||
| Mutants of Saccharomyces cerevisiae that block intervacuole vesicular traffic and vacuole division and segregation | Q37686250 | ||
| Redundant expression of canonical Wnt ligands in human breast cancer cell lines | Q40319189 | ||
| Regulated expression of Wnt family members during proliferation of C57mg mammary cells | Q41490498 | ||
| Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. | Q42467556 | ||
| Flow-induced calcium oscillations in rat osteoblasts are age, loading frequency, and shear stress dependent | Q42511426 | ||
| Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength | Q46186977 | ||
| Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal | Q46463830 | ||
| Suppression of the osteogenic response in the aging skeleton | Q68105162 | ||
| Expression patterns of beta-catenin in in situ and invasive breast cancer | Q73584788 | ||
| Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer | Q73603290 | ||
| Age-related decreases in stimulatory G protein-coupled adenylate cyclase activity in osteoblastic cells | Q73847735 | ||
| Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours | Q24292176 | ||
| Osteocyte control of bone formation via sclerostin, a novel BMP antagonist | Q24300347 | ||
| SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor | Q24303393 | ||
| Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism | Q24305585 | ||
| TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro | Q24557552 | ||
| Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways | Q24621990 | ||
| Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist | Q24646652 | ||
| Osteoclasts: what do they do and how do they do it? | Q24683898 | ||
| Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling | Q28240767 | ||
| Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation | Q28285151 | ||
| Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody | Q28286616 | ||
| Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis | Q28302443 | ||
| Examination of nuclear receptor expression in osteoblasts reveals Rorβ as an important regulator of osteogenesis | Q28509668 | ||
| Age-related changes in gap junctional intercellular communication in osteoblastic cells | Q28575787 | ||
| Differential transformation of mammary epithelial cells by Wnt genes | Q28646632 | ||
| Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer | Q33860808 | ||
| Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease | Q33891844 | ||
| Minireview: the OPG/RANKL/RANK system | Q34102256 | ||
| Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age | Q34285855 | ||
| Beta-catenin and Tcfs in mammary development and cancer | Q34543461 | ||
| Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. | Q35059311 | ||
| Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. | Q35230055 | ||
| Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation | Q35991461 | ||
| Impairment of osteoblast differentiation due to proliferation-independent telomere dysfunction in mouse models of accelerated aging | Q36103691 | ||
| Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells | Q36223256 | ||
| Building bone to reverse osteoporosis and repair fractures | Q36407024 | ||
| Osteoporosis: now and the future | Q36564425 | ||
| Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. | Q37015968 | ||
| Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. | Q37163219 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1901-1907 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Journal of Cellular Biochemistry | Q6294917 |
| P1476 | title | Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization | |
| P478 | volume | 114 |
| Q33557188 | Ageing in the musculoskeletal system |
| Q33882124 | Aging diminishes lamellar and woven bone formation induced by tibial compression in adult C57BL/6 |
| Q51666670 | Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status. |
| Q33564617 | Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions |
| Q37423382 | Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans |
| Q37428990 | Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women |
| Q90451142 | Friend or Foe? Essential Roles of Osteoclast in Maintaining Skeletal Health |
| Q53527845 | Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis. |
| Q35149611 | LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. |
| Q37414413 | Mechanisms of osteoclast-dependent bone formation |
| Q94570102 | Nephrectomy Does not Exacerbate Cancellous Bone loss in Thalassemic Mice |
| Q39190775 | Osteoblast-osteoclast interactions |
| Q33993757 | Osteoclasts: more than 'bone eaters'. |
| Q30619950 | Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone |
| Q27022407 | Osteocytes: master orchestrators of bone |
| Q89820667 | Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System |
| Q47977236 | Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin |
| Q38807230 | Role and mechanism of action of sclerostin in bone |
| Q36247366 | Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement |
| Q51303428 | Sclerostin expression and functions beyond the osteocyte. |
| Q57813864 | Sclerostin promotes human dental pulp cells senescence |
| Q90406658 | Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review |
| Q47909734 | Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease. |
| Q37387761 | Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner. |
| Q97088370 | Titanium particles damage osteocytes and inhibit osteoblast differentiation |
Search more.